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In this study we estimate the seroprevalence of foot-and-mouth disease virus (FMDV) in wildlife from
eastern and central Africa. Sera were sourced from between 1994 and 2002 from a rinderpest surveillance
program. Our study compared a nonstructural protein enzyme-linked immunosorbent assay (Cedi test) with
a virus neutralization test. The study shows that there is only a low seroprevalence of FMDV in sampled
nonbuffalo species. The seroprevalence in the Cape buffalo was high for SAT2, lower for SAT1, and lowest for
SAT3. As the SAT2 serotype was most prevalent, the Cedi test largely reflected the occurrence of SAT2-positive
animals. The results also suggest that SAT2 became dominant around 1998, with a large increase in sero-
prevalence. The sensitivity and specificity of the Cedi test were estimated by comparison to the combined virus
neutralization test results from all three SAT tests. A Bayesian implementation of the Hui-Walter latent class
model was used to estimate the test parameters. The model permits estimation in the absence of a gold
standard test. The final model, using noninformative priors and assuming conditional independence of test
performance, estimated Cedi test sensitivity at 87.7% and specificity at 87.3%. These estimates are similar to
those for domestic bovines; they suggest that the Cedi test is a useful tool for screening buffalo for infection with
the various serotypes of FMDV.
Foot-and-mouth disease (FMD) is a highly contagious viral
disease of even-toed ungulates (Artiodactyla) caused by the
single-stranded positive-sense RNA foot-and-mouth disease
virus (FMDV; Aphthovirus, Picornaviridae). There are seven
distinct serotypes recognized globally, known as O, A, C,
SAT1, SAT2, SAT3, and Asia1, of which only Asia1 has not
been seen in Africa (25). There is little cross-protection be-
tween serotypes, although it has been suggested that there may
be problems differentiating exposure in multiply infected or
exposed buffalo when using virus neutralization tests (VNT)
(21). In the 1900s, serotypes O, A, and C spread from northern
Africa and into southern Africa (11), while the SAT viruses
spread northwards with sporadic incursions into the Middle
East (45). FMD is one of the most important animal diseases
and has major impacts on a country’s ability to trade in live-
stock and animal products. In order to facilitate trade between
countries and prevent trade barriers, many countries are sig-
natories to the Sanitary and Phytosanitary agreement of the
World Trade Organization. To justify any trade barriers, coun-
tries are required to demonstrate that trade in particular ani-
mals or plants or their products is likely to put them at an
unacceptable risk of disease introduction. To satisfy interna-
tional regulations, these risks need to be assessed as part of a
clear and transparent risk analysis as required by the World
Organisation for Animal Health (OIE).
Wildlife in Africa, particularly the Cape buffalo (Syncerus
caffer), have been identified as natural hosts for the SAT se-
rotypes of FMDV, although they may be infected by all sero-
types (20, 22). Also, the strong spatial associations between
molecular types from outbreaks in cattle and virus recovered
from buffalo suggest that any control strategy for FMD in
cattle must address control in buffalo (43). This differs from the
general situation in other parts of the world, where control in
cattle has tended to result in disappearance of the disease in
wildlife populations, and probably reflects the importance of
buffalo as a natural reservoir (42). Cattle in many areas of
Africa are managed on open rangeland with communal grazing
and potential contact with wildlife populations. This wildlife-
livestock interface is critical for disease transmission, particu-
larly around common watering points and through contamina-
tion of grazing. In southern Africa FMD control has relied
upon wildlife fences to keep cattle and buffalo separate, com-
bined with vaccination in buffer zones (40, 43, 45). The planned
global eradication of FMDV will require control in buffalo in
Africa and a better understanding of the epidemiology in wild-
life, particularly in Africa. Serosurveillance will be improved by
using the new nonstructural protein (NSP) enzyme-linked im-
munosorbent assays (ELISAs) now available, which offer the
potential to identify animals seropositive for any of the seven
serotypes in a single, affordable test (3, 4, 14, 28–30, 34, 35).
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This paper describes FMDV serology using the Cedi NSP
assay and VNT for the three SAT serotypes. A Bayesian latent
class model was used to estimate the parameters (sensitivity
and specificity) of the Cedi test and the seroprevalence in the
different regions in the absence of a gold standard test for
these populations (17).
MATERIALS AND METHODS
Study populations and sampling. Serum samples were collected from wild
ungulates, including buffalo, antelope, and warthogs. These animals were from
eastern and central Africa and were originally sampled as part of a wildlife health
surveillance project run by the Kenya Wildlife Service, the Pan African Rinder-
pest Eradication Campaign, and the Programme for the Control of Epizootics
from 1994 to 2005, under the auspices of the African Union Inter African Bureau
for Animal Resources (IBAR). Serosurveillance for rinderpest virus antibodies
in wildlife populations in eastern and central Africa became an important part of
the monitoring of virus activity in the closing stages of eradication (27). The
wildlife were sampled in and around a large number of mainly unfenced parks
and wildlife reserves across eastern and central Africa. Sampled herds were
selected partly on the basis of susceptibility and contact with livestock popula-
tions. All the buffalo populations sampled had contact with livestock, with the
exception of those in Garamba in the Democratic Republic of Congo. Our FMD
serological study is based on a subset of sera taken from the bank and sent to the
Institute for Animal Health (IAH) Pirbright for screening (Table 1). The selec-
tion was made to provide the widest coverage of the sampled zones possible. It
focused on the Cape buffalo, a preferred host for FMD virus. The serum samples
were obtained from free-ranging wildlife after immobilization by either physical
restraint with netting or through remotely injected chemical anesthetic agents
(etorphine hydrochloride with a variety of sedative or tranquilizers, e.g., xylazine
and acepromazine). Different national teams were used, but all of them were
supervised and supported in the field by the wildlife health specialist from the
African Union IBAR. A total of 731 sera from 27 species from Kenya, Tanzania,
Ethiopia, Sudan, and Chad were screened for FMD virus antibody using a Cedi
test FMDV-NS test kit (Cedi Diagnostics B.V.) and by VNT for SAT1, SAT2,
and SAT3.
NSP serology. The Cedi test FMDV-NS test (Cedi test) is a blocking ELISA
that detects antibodies against the nonstructural 3ABC protein of FMDV. It is
independent of serotype and may be used to detect exposure in vaccinated
animals. In addition, as a blocking ELISA it can be used for all species without
the need for a species specific antigen. This test has not been validated for use
in wildlife species. The monoclonal antibody (MAb) is based on European
viruses (34), so the test can be expected to perform suboptimally for African
viruses and the immune response may be as short as 40 days. This means that
exposed animals may test negative. Test plates in the kit have been coated with
a 3B-specific MAb and incubated with the 3ABC protein, resulting in FMDV-NS
antigen bound to the coated MAb. The tests were carried out according to the
manufacturer’s instructions and as previously reported (36). All samples were
tested in duplicate. Plates were read by measuring the optical density (OD) at a
wavelength of 450 nm. The ODs of all samples including the controls were
calculated and are expressed as the percent inhibition (PI) as follows: PI  100 
[(OD of test sample)/(mean OD of negative controls)]  100.
A PI of 50% was considered negative, and a PI of 50% was considered
positive for recent exposure (within the previous 6 to 12 months) (7, 14). More
specifically, a PI value of50% but70% was considered a weak positive result,
and a PI value of 70% was considered a strong positive result (36).
VNT. Titers of neutralizing antibodies of all wildlife sera against FMDV
SAT105, SAT2 Eritrea, and SAT309 were measured by microneutralization
assay as described in the OIE Manual of Diagnostic Tests and Vaccines (31).
Serum samples which were found positive by Cedi test and negative by all three
SAT tests were examined for the titers of neutralizing antibodies against O1
Manias, A22 Iraq, C Noville, and Asia Shamir (ISR 3/89). The cutoff for posi-
tivity with the VNT was a titer of 1:45.
Statistical analysis. Cedi test and VNT results for each animal were recorded
in an Excel spreadsheet (Microsoft Corp.) with species, age, sex, sampling loca-
tion, and sampling date. An animal which was VNT positive for any SAT
serotype was considered VNT SAT positive. The analysis was repeated with a
combined VNT for all serotypes but this did not change the results of the
parameter estimates, and these data are not included in this paper.
Descriptive statistical analysis was carried out using the R program (http:
//www.R-project.org). The proportion of samples positive by the Cedi test was
estimated for each species as well as by year and by age group for the buffalo
samples. The Bayesian latent class model was parameterized using the BRugs
package (41) in R, an open access version of WinBugs (38). Convergence of the
chains and stability of the estimates was assessed using the Gelman-Rubin
statistic (10, 44). The Hui-Walter latent class analysis requires that the buffalo be
divided into three distinct subpopulations. This was done geographically using
the K-cluster function in Minitab 14 (Minitab Inc.) with the latitude and longi-
tude of the location of each sampled buffalo. Geographical clustering with K-
means clustering was used to generate three spatially distinct populations that
would have some epidemiological meaning. Randomly allocation to three groups
would risk generating three populations with an almost identical prevalence,
which would causes poor identifiability for the model.
The no gold standard model. The sensitivity (Se) of a diagnostic test is the
probability of a positive test result conditional on the animal being infected or in
this case truly seropositive and can be expressed as Pr(T D). The specificity
(Sp) of a diagnostic test is the probability of a negative test result conditional on
the animal not being infected or in this case truly seronegative and can be
expressed as Pr(T D). The basic Hui-Walter latent class model (23) assumes
that the test parameters (Se and Sp) are constant across all populations and that
the tests are conditionally independent given the true status of the animal, i.e.,
given an animal’s status, knowing the result of the first test does not change the
likelihood of a particular result with the second test. We ran several versions of
the model, starting first with the simplest three-population two-test model, as-
suming test conditional independence and uniform priors on test performance.
The latent class model can be expressed as follows: Oi Sej,Spj,pi  multinomi-
nal(Pri, ni) for populations i  1 to 3 and tests j  1, 2, where Oi is the vector of
observed counts for test 1 and test 2 for all four possible combinations of the two
tests for population i (, , , and ) taken from the two-by-two
contingency table and Pri is a vector of probabilities for each count in the table
for each population i. For example, the probability of being VNT and Cedi test
positive in population i can be written as Pri()  Se1 Se2 pi  (1  Sp1)(1 
Sp2)(1  pi), where Se1 is the sensitivity of the first test, Sp1 is the specificity of
the first test, Se2 is the sensitivity of the second test, Sp2 is the specificity of the
second test, and pi is the true seroprevalence in population i (in this model, this
will be 1, 2, or 3).
The Bayesian model allows the use of prior information about the test to be
included in the estimation process, and this can be thought of as our belief of the
distribution of the possible estimates of Se and Sp prior to looking at our new
data. This explicitly allows us to state how certain we are about the test and then
to combine this with the data from the study to get a posterior belief, which is a
TABLE 1. Species sampled
Species No. sampled
Buffalo, Syncerus caffer....................................................................483
African and desert warthog, Phaecocherus africans
and P. aethiopicus ........................................................................ 52
White-eared kob, Kobus leucotis ................................................... 50
Giraffe, Giraffa camelopardalis ...................................................... 34
Eland, Taurotragus oryx .................................................................. 19
Thomson’s and Grant’s gazelle, Gazella thomsoni
and G. grantii ............................................................................... 17
Impala, Aepyceros melampus.......................................................... 13
Lelwel, Swayne’s, and Coke’s hartebeest, Alcelaphus
buselaphus lelwel, A. buselaphus swaynei,
and A. buselaphus buselaphus .................................................... 14
Lesser and greater kudu, Tragelaphus imberbis
and T. strepsiceros ........................................................................ 9
Topi or tiang, Damaliscus lunatus................................................. 9
Beisa and fringe-eared oryx, Oryx beisa and O. gazella .............. 7
Cow, Bos indicus.............................................................................. 4
Roan antelope, Hippotragus equinus............................................. 7
Wildebeest, Connochaetes taurinus ............................................... 5
Hirola, Beatragus hunteri ................................................................ 3
Bushbuck, Tragelaphus scriptus ...................................................... 1
Gerenuk, Litocranius walleri .......................................................... 1
Mountain nyala, Tragelaphus buxtoni............................................ 1
Sable, Hippotragus niger .................................................................. 1
Waterbuck, Kobus ellipsyprimnus defassa ..................................... 1
Total..................................................................................................731
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weighted estimate based on our prior belief and the data. We then used prior
distributions for the Cedi test taken from a review of the Cedi test’s performance
(6). These were SeCEDI TEST Beta (1.4, 1.2) and SpCEDI TEST Beta (99, 6), which
reflect a lack of certainty about the true estimate of the test’s Se and a high level
of certainty about the estimate of the test’s Sp.
As both of the test systems are based around antibody responses, it is likely
that there is some conditional dependence in the tests (18). In other words, given
that we know the test result from one test, we can know more about what the
result of the other test is likely to be, over and above if we knew the infection
status. This may lead to biased estimates, as it violates one of the fundamental
assumptions of the Hui-Walter model. Therefore, we used a modified version of
this model, allowing for conditional dependence between tests, by inclusion of
the covariance of test results for disease-positive (covD) and for disease-neg-
ative groups (covD) (5). The new model can be written as follows: Oi
Sej,Spj,pi,covD,covD  multinominal(Pri, ni) for populations i  1 to 3 and
tests j  1, 2, where Oi is the vector of observed counts for test 1 and test 2
cross-tabulated in a two-by-two table (,,, and) and Pri is a vector
of probabilities for each count in the table summing to 1 for each population i.
For example, Pr( )  [(Se1 Se2)  covD]pi  [(1  Sp1)(1  Sp2) 
(covD)(1  pi), and Pr( )  [Se1(Se2  1)  covD]pi  [(1  Sp1)Sp2 
covD(1  pi)].
We had no prior information on the two covariances, so we used uniform priors
such that the covariance between the test outcomes for infected animals would
satisfy the following criteria: (Se1  1)(Se2  1)  covD  min(Se1;Se2) 
(Se1)(Se2), and for the noninfected subpopulation, (Sp1  1)(Sp2  1) covD 
min(Sp1;Sp2)  (Sp1)(Sp2) (see reference 15).
Therefore, for instance, a uniform (Se1  1)(1  Se2); min(Se1;Se2) 
(Se1)(Se2) prior distribution can be used for covD.
The three population two-by-two cross-tabulations for each test (see Table 6,
below) were used to update the model. For each model, the first 5,000 iterations
were discarded as burn-in and the next 20,000 iterations, using two chains, were
used to parameterize the model. The convergence of the chains was assessed
using the Brooks-Gelman-Rubin diagnostics (10, 44). Goodness of fit was also
measured using the deviance information criterion (DIC) which penalizes good-
ness of fit by “complexity” (37). The 95% credibility intervals are similar to the
more widely used confidence intervals but, in contrast to the common misinter-
pretation of the confidence interval, the credibility interval is the range within
which the true population value lies with 95% probability.
The maps were generated using ArcGISv9.0 (ESRI, Redlands, CA).
RESULTS
Descriptive analysis: nonbuffalo wildlife. The PIs from the
Cedi tests for each species are presented in Fig. 1. There were
only small numbers of animals sampled from most species
other than buffalo (Table 1); most of the nonbuffalo animals
were seronegative on the Cedi test. Of the 248 nonbuffalo
wildlife samples tested, 11 were positive by the Cedi test and
included seven different species that varied in age and sex.
However, not all these were positive by the VNT. All of the
Cedi-positive samples were collected in 1999 and 2000 with the
exception of the eland, which were sampled in 1996. Nine out
of 10 animals (one had no age recorded) were above the age of
3, the other being an approximately 10-month-old gazelle.
Only 3/11 had PIs of 70%, while 7/11 had very weak positive
PI values between 50 and 56%. The warthogs ranged in age
from 1 to 10 years, and the kobs ranged from 3 months to 7
years of age. The geographical distribution of the various pos-
itive nonbuffalo animals was dispersed across the study area.
The results of the VNT also showed a very low seroprevalence,
with only 14/248 seropositives in a range of species that in-
cluded gazelles, giraffe, and impala. A total of 4/22 were pos-
itive by both tests: 11/22 were VNT positive Cedi negative, and
7/22 were Cedi positive VNT negative.
Descriptive analysis: buffalo. Sampling was carried out be-
tween 1994 and 2004. Positive Cedi test samples were seen in
buffalo for all 10 years. The PI values for all wildlife and for
buffalo only are plotted in Fig. 2. This suggests a bimodal
distribution, reflecting the seropositive (mainly buffalo) and
seronegative (mainly nonbuffalo animals) populations, with a
center around 20% for nonbuffalo animals and a very left-
skewed distribution for the buffalo. A total of 327 out of 483
(67.7%) buffalo tested positive for FMDV NSP antibodies with
232 strong positives (70) and 95 weak positives (50 and
70). The proportion of male and female Cedi test-positive
buffalo positive for FMDV NSP antibodies was not statistically
significantly different (Table 2). The age-stratified and year-
stratified summaries of PIs are plotted in Fig. 3A and B. There
are very few buffalo calves in the sample, but the data suggest
animals seroconvert very early in life, with the age-stratified
FIG. 1. Box plot of Cedi test results for all species sampled. A PI
value of 50% indicates a positive test result. , outlier.
FIG. 2. Histogram of the Cedi test PI for all species and for buffalo
only.
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seropositive proportion increasing to over 60% by 9 months
(Table 3). This remains over 60% until the animals are over 15
years old, when there is a slight decline.
The proportions of seropositive buffalo samples overall by
the VNT for SAT serotypes were 37.3% for SAT1, 67.1% for
SAT2, and 17.0% for SAT3. The age-stratified seroprevalence
for each test is given in Fig. 4. The SAT1 profile suggests early
exposure, and then the proportion remains very similar at
around 40%. The proportion of SAT2 seropositivity rises to
around 70% by 5 years and is stable thereafter. The proportion
of SAT3 seropositives is much lower but appears to increase
slowly with age. The proportion of Cedi test seropositives
largely matches that for SAT2, since this is the predominant
serotype. Among the buffalo sampled from eastern Africa, 301
were positive by both Cedi and VNT SAT, 26 were positive by
Cedi but negative by VNT SAT, 69 were negative by Cedi but
positive by VNT SAT, and 87 were negative by both tests
(0.803% agreement; kappa  0.151; Yules Y  0.585). The
SAT VNT results by serotype, alone and in combination, are
shown in Tables 4 and 5.
The difference in seroprevalence by year is given in Fig. 5.
This gives a variable pattern for SAT1 seroprevalence, with
wide fluctuations by year. SAT3 prevalence is low until the
2000s with considerable variation. SAT2 seroprevalence shows
more of a pattern with an apparent increase in proportion
seropositive by year up to 2000 and then remains high at
around 70 to 80%. The Cedi test again seems to largely reflect
the SAT2 results, since this is the dominant serotype.
The geographical distributions of the buffalo sampled and
their seropositivity for the Cedi test and SAT VNTs are
mapped in Fig. 6. There was a small increased odds of sero-
positivity (odds ratio, 1.15) with large herd size (50) com-
pared to small herd size (50), but this was not statistically
significant (P  0.51).
Test parameter estimation in buffalo. The means and 95%
credibility intervals for the three models are summarized in
Tables 6, 7, and 8. The sensitivity and specificity of the Cedi
test were 0.877 and 0.873 for the model assuming conditional
independence and uninformative priors (model 1; i.e., we had
no strong beliefs about the test parameters in buffalo from
previous studies), compared to 0.872 and 0.942 for the model
assuming conditional independence but with informative pri-
ors (model 2; i.e., we had strong beliefs about the Sp and less
strong beliefs about the Se), and 0.852 and 0.941 for the model
including dependence and informative priors (model 3; i.e., we
had a strong belief about the Sp and a less strong belief about
the Se and thought there may be dependence between tests).
The model that included dependence but used uninformative
priors was not identifiable. For the three models described,
there was good convergence and mixing of the chains based on
the Brooks-Gelman-Rubin plots. The fit of each of the models
was also compared using the DIC, and there did not appear to
be an important difference in fit. The models all estimate the
FIG. 3. Box plots of Cedi test result versus age group (A) and year
of sampling (B). The number of animals sampled in each age category
is proportional to the width of the box. , outlier.
TABLE 2. Cedi test results from male and female buffaloa
Sex
No. of buffalo Proportion of buffalo
that tested positive
(95% CI)Positive Negative Total
Male 137 56 193 0.710 (0.646–0.774)
Female 184 92 276 0.667 (0.611–0.722)
Total 321 148 469 0.684
a The sex of the animal was not recorded for 14 samples, and these were
excluded from this analysis. Pearson 2(1)  0.9804; P  0.322.
TABLE 3. Cedi test results for buffalo, by age categorya
Age category
No. of buffalo % of buffalo that
tested positivePositive Total
0–9 mos 1 3 33.3
9–18 mos 51 80 63.8
18 mos–5 yrs 144 201 71.6
5–10 yrs 79 115 68.7
10–15 yrs 42 61 68.8
15 yrs 7 13 53.9
a Ages were not available for 10 animals.
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seroprevalence of FMDV to be highest in the central popula-
tion and lowest in the coastal population. The models also give
slightly different estimates of Se and Sp for each test, as might
be expected, and the trade-offs of these models are discussed in
more detail in the Discussion.
DISCUSSION
The Cedi FMDV-NS test was used to screen the sera be-
cause, as a blocking ELISA, it is species independent and as
such should be a good choice for testing wildlife samples from
a range of species. In addition, antibodies to the 3ABC protein
are considered to be a reliable indicator of infection/exposure
regardless of vaccination status and of the serotype of FMDV
(36, 39). However, it cannot distinguish between different se-
rotypes.
The seroprevalence estimates in nonbuffalo species were
very low based on either the VNT SAT or Cedi test results.
However, there does not appear to be very good agreement on
individual positive samples between the tests for nonbuffalo.
There were insufficient samples to do a more through analysis
of the Cedi test in these species, but clearly it would be useful
to have better estimates of its performance in a wider range of
species.
The Cedi test detected 11 seropositives, but only 4 animals
were positive in both test systems. In addition, the distribution
of OD readings, although appearing bimodal, did not suggest
a clear cutoff. The low seroprevalence by VNT in nonbuffalo
species is comparable to the results of a survey done between
the years 1989 and 1992 that found only 1 to 2% of 7,970 wild
ungulates of 14 different species were positive for FMDV (1).
The nonbuffalo wildlife sampled in this study overlapped spa-
tially with the sampled buffalo that were seropositive but ap-
FIG. 4. Age-stratified seroprevalence rates based on the Cedi test and VNTs for SAT1, SAT2, and SAT3.
TABLE 4. SAT VNT seropositive buffalo from 483 sampled
SAT VNT No.positive
SAT VNT
result
Total no. VNT
positive
SAT1 only 34 SAT1 180
SAT2 only 165 SAT2 324
SAT3 only 2 SAT3 82
SAT1/2 89
SAT1/3 10
SAT2/3 23
SAT1/2/3 47
TABLE 5. Cross-tabulation of test results for the combined VNT
for the three SAT serotypes and the Cedi test ELISA
for the three populations of buffaloa
Populationb and Cedi test result
VNT SAT result
No.
positive
No.
negative
1, Kenya/Tanzania border (4.8093	N, 28.7044	E)
No. positive 73 12
No. negative 17 15
2, Central Kenya (4.6801	N, 34.0813	E)
No. positive 72 2
No. negative 11 4
3, Coastal Kenya (1.4953	N, 38.3619	E)
No. positive 156 12
No. negative 41 68
a Results were generated using K means in Minitab.
b The coordinates of the center for each of the three populations are also
given.
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pear not to have seroconverted by and large, suggesting some
level of resistance if one assumes that they have been exposed
through contact with buffalo.
It is interesting that only two warthogs were seropositive by
VNT and not by Cedi, although domestic pigs are known to
excrete significant quantities of virus at the time of infection
(26). The number of samples from other species of wildlife
FIG. 5. Seroprevalence based on the Cedi test and VNTs for SAT1,
SAT2, and SAT3 stratified by year of sampling.
FIG. 6. Distribution of seropositive buffalo sampled between 1994 and 2004. Note that colored circles mark positive results (green, Cedi test;
yellow, SAT1; purple, SAT2; orange, SAT3), and an X marks samples that were seronegative.
TABLE 6. Parameter estimates from Bayesian formulation of the
Hui-Walter latent class model based on 20,000 iterations after
convergence model 1a
Parameter Mean SD 2.5% BCI 97.5% BCI
p coastal 0.766 0.0721 0.610 0.888
p central 0.924 0.0417 0.824 0.985
p border 0.651 0.0553 0.539 0.753
Se Cedi test 0.877 0.0398 0.803 0.959
Se VNT 0.952 0.0248 0.904 0.996
Sp Cedi test 0.873 0.0713 0.735 0.993
Sp VNT 0.757 0.1000 0.578 0.964
a Model 1 assumes conditional independence using uniform priors for both
tests based on 20,000 iterations (DIC  57.79). BCI, Bayesian credible interval.
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were relatively small, but they suggest, particularly for the
warthog species (Phaecocherus african, P. aethiopicus) and kob
(Kobus leucotis), that there had been no recent exposures.
These results support previous studies (43) in showing
clearly that buffalo (Syncerus caffer) have very high seropreva-
lences to FMDV by both the Cedi test and by serotype-specific
VNTs. In these buffalo populations SAT2 was the most dom-
inant serotype, followed by SAT1 and then SAT3. The data
suggest that there has been a marked increase in prevalence of
FMDV overall with a shift to SAT2 dominance around 1998. It
is interesting that the age-stratified seroprevalence appears to
be relatively constant at around 60 to 70% based on the Cedi
and SAT2 results across all ages after about 9 months. The
reasons for this are not clear, as one might expect that with
virus and carrier animals in endemic areas there would be high
continuous exposure keeping titers higher. It may reflect the
effect of the sampling and spatial components that we have not
been able to demonstrate but that reflect a more epidemic
pattern, with some populations having lower seroprevalences
at certain times but overall giving the appearance of a constant
level.
The lack of an increased odds of being seropositive for small
versus large herds is evidence for continuous herd-level circu-
lation of SAT2 (and possibly SAT1 and SAT3), as each herd
shows a reasonably discrete subpopulation but on occasions
aggregation and/or fragmentation of herds occurs, with sea-
sonal or breeding cycles providing opportunities for cross-herd
transmission. This is consistent with population-level preva-
lence across herds in a given ecosystem, which is also high,
providing evidence of circulation across the population as well.
Very few SAT3-seropositive animals were only seropositive
for SAT3, while a higher proportion were SAT1 seropositive
only or SAT2 seropositive only. The majority of samples pos-
itive to more than one serotype were SAT2 positive, and this
raises the issue of to what extent the SAT results (particularly
SAT3) are cross-reactions. Although the SAT1 may be a cross-
reaction, interestingly, none of the buffalo sampled in Tchad
were SAT1 positive. Most were SAT2 positive, with only two
SAT3 positives (21). Without concurrent probangs and virus
isolation, it is not possible to separate these and identify how
many are cross-reactions and how many are genuine seroposi-
tives.
Although there may be some discussion of the precise esti-
mates of sensitivity and specificity of the all of the tests, it is
clear that the seroprevalence of FMDV in Cape buffalo in
eastern Africa is very high and that animals appear to sero-
convert very early in life, probably within the first 1 to 2 years.
This is certainly consistent with the situation further south in
Africa, where they are the primary wildlife species acting as a
reservoir for FMDV in southern Africa (2, 13). There is also
some evidence in the data to suggest that the seroprevalence
increased through the late 1990s, although SAT2 viruses have
been recorded from the region since 1958 (45). However, there
were reported outbreaks in Kenya (1994 to 2000), Tanzania
(1999 to 2000) and Uganda (1995 to 1999) of SAT1, SAT2, and
O (as well as A and C in Kenya) (45). Although buffalo are
considered to be the main reservoir of the SAT serotypes, the
apparent seroprevalences of SAT1 and SAT3 were low, and
based on the NSP test there is little evidence that other sero-
types were circulating in the buffalo populations. This may
mean that buffalo are not maintaining these serotypes in the
region; rather, there may be maintenance in cattle or regular
reintroductions from beyond due to cattle movements. This
needs to be looked at in more detail, however, with molecular
epidemiology tools.
Comparison of the seroprevalence of FMDV in buffalo to
the seroprevalence of FMDV in livestock held in similar areas
during the time period of the wildlife sampling would be in-
teresting and could possibly shed light on the role that buffalo
have in transmission of the disease to domestic livestock. The
role of carrier buffalo is a particularly important aspect for
control programs, and this needs further study. Dawe et al.
(12) demonstrated natural transmission from carrier buffalo to
cattle, as well as experimental transmission (13). However,
transmission from carrier cattle appears to be much less likely
and has not been demonstrated under experimental conditions
(16). In cattle it has been seen that although the virus could be
isolated up to 57 (19) or 98 (32) days postchallenge from
vaccinated and challenged animals, introducing naı¨ve cattle for
direct contact with these carrier animals could not transmit the
disease.
Data on outbreaks in cattle at the time of sampling were
generally not available except from Western Laikipia in Kenya,
where there were reports of outbreaks of type O in cattle in
October 2002 and samples from the buffalo in the area at the
same time were seropositive for SAT2 (19/20), SAT1 (7/20),
and SAT3 (2/20). There is little published on non-SAT sero-
types in buffalo, but it is unlikely that this type O has come
TABLE 7. Parameter estimates from Bayesian formulation of the
Hui-Walter latent class model based on 20,000 iterations after
convergence model 2a
Parameter Mean SD 2.5% BCI 97.5% BCI
p coastal 0.808 0.0551 0.687 0.902
p central 0.931 0.0376 0.844 0.989
p border 0.676 0.0469 0.582 0.764
Se Cedi test 0.872 0.0386 0.803 0.954
Se VNT 0.932 0.0169 0.898 0.965
Sp Cedi test 0.942 0.0230 0.889 0.978
Sp VNT 0.772 0.0975 0.593 0.966
a Assumes conditional independence with informative priors for the Cedi test.
Se  Beta(1.3,1,2); Sp  Beta(99,6); DIC  57.019. BCI, Bayesian credible
interval.
TABLE 8. Parameter estimates from Bayesian formulation of the
Hui-Walter latent class model based on 20,000 iterations after
convergence model 3a
Parameter Mean SD 2.5% BCI 97.5% BCI
covDn 0.013 0.0182 0.0168 0.0533
covDp 0.015 0.0168 0.0077 0.0543
p coastal 0.833 0.0604 0.705 0.943
p central 0.948 0.0386 0.852 0.008
p border 0.692 0.0518 0.591 0.792
Se Cedi test 0.852 0.0426 0.773 0.942
Se VNT 0.911 0.0266 0.852 0.956
Sp Cedi test 0.941 0.0232 0.888 0.978
Sp VNT 0.753 0.1041 0.560 0.969
a Model 3 assumptions include dependence between tests with informative
priors for the Cedi test based on 20,000 iterations (DIC  57.64). BCI, Bayesian
credible interval.
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from the buffalo as the reservoir. From reported outbreaks in
Saharan Africa (45) it appears that the majority of outbreaks in
the southern regions are due to SAT serotypes with only spo-
radic introductions of O and A. Since this is also the region
where most work has been carried out in buffalo, this is re-
flected in the lack of information of other serotypes in this
species.
It is a concern that serum that has been repeatedly freeze-
thawed could produce less sensitive test results (36). For the
FMD survey, some of the wildlife sera were over 10 years old,
as samples were collected from 1994 to 2004. Repeated freeze-
thawing also occurred since collection, because originally the
samples were tested in eastern and central Africa for rinder-
pest before being shipped to the United Kingdom to be tested
for FMDV. Recent work on sera at Pirbright that examined
the consistency in results of antibody screening repeatedly over
long storage periods showed remarkable stability in antibody
detection by VNT and competitive ELISA (S. Hargrove, per-
sonal communication). Despite the lower relative sensitivity of
88% for the 3ABC ELISA, it is a specific and precise test that
can be used on populations of animals regardless of species or
serotype of FMDV.
The sensitivity and specificity of the 3ABC ELISA (Cedi
test) have not previously been estimated for wildlife such as
buffalo. Estimates for the sensitivity relative to the VNT results
in sheep are reportedly 92%, and for cattle the value is lower
at 88%. The relative specificities are higher for both sheep and
cattle, between 100% and 99.8%, respectively (36). Recent
studies comparing several NSP tests, including the Cedi test,
have produced a range of estimates. In cattle the sensitivity
ranged from 50.0 to 100.0, depending on how long after infec-
tion animals were tested, while the specificity was much more
precisely estimated and ranged from 97.2 to 99.0% (6, 33).
These estimates formed the basis of the prior distributions
used in our latent class models where informative priors were
used. These are, of course, based largely on experimental stud-
ies (particularly the sensitivity estimates) and on cattle and
may in fact not be a very reliable guide to their performance in
buffalo. There are also potential problems with using a com-
bined VNT as a second test for an NSP test, because the
durations of VNT antibodies and NSP antibodies differ, as
does the rate of seroconversion (9). However, the other com-
mercially available kits produced by Svanova, Bommeli, and
UBI are not suitable, as they need species-specific conjugates
and no wildlife conjugates are available.
The parameter estimates for the Cedi test in buffalo based
on the latent class modeling approach suggest that the Cedi
test is sensitive and very specific in the buffalo populations of
eastern Africa. The specificity for models where an informed
prior was used was driven by this prior. Including dependence
in the model did not change this. However, using a noninfor-
mative prior, which may be more appropriate for this popula-
tion, reduced the estimated specificity to 87%. The sensitivity
on the other hand changed little between models, as the in-
formed prior was very diffuse and added little to the noninfor-
mative case, with both producing estimates around 87%. The
inclusion of dependence in the model resulted in a slight low-
ering of the estimate to 85%. The covariances for both the
sensitivity and specificity of the two tests were low, indicating
that the assumption of independence may be valid, and cer-
tainly there is little change in the DIC when it is dropped.
The most appropriate model of the three presented is a
matter for discussion. The more conservative approach would
be to use model 1, which makes no assumptions about the test
parameters in buffalo, as the informative priors used in models
2 and 3 come from cattle studies. For model 3, which included
dependence, the test covariances were very small (covsp,
0.01296; covse, 0.01519), and therefore there does not appear
to be a problem of dependence between the tests; if we wish to
use the priors, model 2 would therefore appear to be a rea-
sonable model.
Although the aim was not to estimate the sensitivity or
specificity of the combined VNT for SATs, the estimates
gained could be useful for other work. The low estimated
specificity of all the models is worrying, given that the VNT is
considered the gold standard. However, this must be inter-
preted in terms of the very different tests and the antibody
profiles of neutralizing and NSP antibodies over time postin-
fection.
Control of FMD in eastern and central Africa is currently
unrealistic, as there is a lack of infrastructure to sustain inten-
sive vaccination campaigns and a lack of new vaccines that can
produce high and sustained neutralizing antibody titers (24). In
addition, Africa will need to also manage FMD in its wildlife or
at least in the buffalo populations across the region in order to
prevent continuous reintroduction. Contact between free-
ranging buffalo in southern Africa is well-recognized (12), and
there is some statistical evidence for increased risk to cattle
herds in central Africa (8). In southern Africa the problem has
been managed through the use of game fencing to keep live-
stock and wildlife separate (40). However, this is relatively
straightforward in southern Africa, where they are at the
southern edge of the natural range for the Cape buffalo. In
eastern and central Africa, where there are still major buffalo
populations mixed with cattle and other livestock, the problem
is much more difficult. However, one possibility, as in South
Africa, is for the development of FMD-free buffalo herds.
Being able to screen them cost-effectively would be a key
element in developing such policy. The Cedi test certainly
offers a potentially useful tool for screening herds. In the early
stages of control the lower specificity will not cause too many
problems. However, as seroprevalence and disease decline the
predictive value of a positive test will be very poor on an
individual basis, though it can still provide useful information
at the herd level, particularly if it is combined with a second
test or other type of testing, such as probanging.
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